Identification of Distinct Disease Activity Trajectories in Methotrexate‐Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty‐Four Months

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). To better understand tofacitinib treatment responses, we used group‐based trajectory modeling to investigate distinct disease activity trajectories and associated baseline variables in patients with activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Bykerk, Vivian P., Lee, Eun Bong, van Vollenhoven, Ronald, Gruben, David C., Fallon, Lara, Woolcott, John C., Keystone, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303215/
https://www.ncbi.nlm.nih.gov/pubmed/34057820
http://dx.doi.org/10.1002/acr.24709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303215/
https://www.ncbi.nlm.nih.gov/pubmed/34057820
http://dx.doi.org/10.1002/acr.24709

Ejemplares similares